Thrombophylaxis in Transurethral Surgery
Conditions
Keywords
thrombophylaxis and transurethral surgery
Brief summary
The rationale for thrombophrophylaxis is well known. Without prophylaxis the incidence of objectivlely confirmed, hospital-acquired deep venous thrombosis is approximately 10% to 40% among medical or general surgical patients. In urology the prevalence is 15-40%. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy1 recommend against specific prophylaxis in patients undergoing transurethral procedures. Our study is the first double-blind, placebo-controlled study with Dalteparine as thrombophrophylaxis in transurethral surgery. The aim of the study is to proof that thrombophrophylaxis causes not more complications in transurethral surgery than without.
Detailed description
The aim of our study is to proof that transurethral surgery under thrombophylaxis with dalteparine is safe. The study design is double-blind placebo controlled.
Interventions
DRUGdalteparine (Fragmin)
transurethrals surgery with and without dalteparine
Sponsors
University Hospital, Basel, Switzerland
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* transurethral surgery
Exclusion criteria
* oral anticoagulation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood loss | intraoperativ, 6 hours post op and 3 days postop |
Countries
Switzerland
Outcome results
None listed